Dr. Anat Cohen-Dayag
President and CEO
Replay available
Compugen (NASDAQ:CGEN) Q1 2020 earnings call, held 2020-05-06. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/compugen-ltd-cgen-q1-2020-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Thank you, Operator, and thank you for joining us today. With me from Compugen are Dr. Anat Cohen-Dayag, President and CEO, Dr. Henry Attaway, Chief Medical Officer, and Ari Krushen, CFO and COO. Before we begin, I would like to read the following regarding forward-looking statements.
0:45 During the course of this conference call, the company may make projections and other forward-looking statements regarding future events or future business outlook, our development efforts and their outcome, our discovery platform, Anticipated progress and timeline for our programs, financing, and accounting-related matters, as well as statements regarding our cash position. We wish to caution you that such statements reflect only the company's current expectations and that actual events or results may differ materially. You are kindly referred to the risk factors and cautionary language contained in the documents the company filed with the Securities and Exchange Commission, including the company's most recent annual report, and Form 20-F filed on February 24, 2020. The company undertakes no obligation to update projections and forward-looking statements in the future. I will now turn the call over to Anat.
1:40 Anat?
1:42 Thank you, Ilana. Good morning and good afternoon, everyone, and welcome to our first quarter 2020 corporate and financial update. As Ilana mentioned, Today on the call, I have with me Dr. Henry Adewoy, our Chief Medical Officer, who will provide updates on our clinical progress. We also have Ari Krashen, our CFO and COO, who will review our financial statements and positions. In the past two months, we have experienced a new reality, brought about by the COVID-19 pandemic, which impacted every aspect of our lives, both private and professional.
2:30 Our highest priority during this time has been and continues to be the safety and health of our employees while doing our best to meet our goals. Most of our employees are currently working remotely, though almost all of our lab scientists continue to work in our R&D laboratories under strict safety guidelines. We have reviewed our most critical activities and implemented mitigation plans to minimize the impact on our clinical programs, which I will discuss in more detail shortly, as well as our early-stage pipeline program.
3:15 Simultaneously with preparing for escalating scenarios nationwide or company-wide, We're now implementing measures which are intended to allow for smooth and efficient recovery once normalization is declared. At this time, we're not experiencing significant delays in our plans, and despite the ongoing challenges associated with the COVID-19 global pandemic, the first quarter of 2020 has been one of significant and continued accomplishments for CompuGem. We reported additional encouraging data from our Phase 1 COM701 dose escalation study, both as monotherapy and in combination with Odevo.
4:04 This further supports the potential of our overall science-driven clinical strategy. In addition, we have advanced COM902, our anti-clinic antibody to the clinic, announcing the first patient dose in April. This marks a third target program discovered computationally by us that is now in clinical studies. Earlier in the quarter, we also announced an important strategic step by spending our ongoing collaboration with Bristol-Mare-Squid to include a Phase I-II-III combination study testing COM701 with BMS of DIVO, and their investigational TIGIT inhibitor.
4:54 This study will enable us to directly test our hypothesis of an intersection between the PDR-IG, TIGIT and PD-1 pathways in which the simultaneous blockade of these three pathways has the potential to synergistically enhance antitumor immune response in selected patient populations Not responsive or refractory to PD-1 blockers alone. As a brief reminder, our intelligent discoveries on the existence of two parallel and complementary pathways in the genome-immune oncology axis lay the foundation for our current progress.
5:39 Our lead program, COM701, originated from our computational discovery of PVRIG as a novel immune checkpoint and newly discovered inhibitory pathway in the genome axis. This finding was added to a prior discovery by us and by others, suggesting that STIGIT, our COM902 target, is an additional inhibitory pathway that is part of the genome axis. Our research and preclinical data indicate that these two pathways are parallel and complementary inhibitory pathways in the genome axis and have further strengthened our belief that in certain tumor types and patient populations, where the two pathways are operative, there may be a need to block both PTRID and TATIC in order to enhance potent anti-tumor immune response.
6:43 Our preclinical data supports recent scientific findings by others indicating a molecular intersection between the genome exit and the PD-1 pathway, thus suggesting that various drug combinations that address PDRG, TGIT, and PD-1 may be required to target these three pathways in different cancer patient populations and in cancer indications. While in some of the patients, blocking the PD-1 pathway will be sufficient, in others, the blockade of one or two of the other inhibitory pathways with or without PD-1 blockade may be required to generate potent immunotherapy treatment responses.
7:36 Before Henry provides detailed clinical updates, I'd like to spend a little more time highlighting our accomplishments and what is to come in 2020. Last week, we presented updated data at the ASTR virtual meeting, which further supports the safety and antitumor activity of COM701 as a monotherapy and expands our data to include also COM701 in combination with Opdivo. As before, we believe our results, which now include two confirmed partial responses, in addition to the high percentage of disease control rate and some durable responses of over six months across treatment arms, are particularly compelling as they were achieved in a dose escalation setting in a highly refractory patient population.
8:38 We have completed the monotherapy dose escalation, and we're now working on completing the combination dose escalation. And importantly, we look forward to beginning our biomarker-informed monotherapy expansion cohort, which are expected in Q2. Our monotherapy expansion cohort will include indications we believe are most likely to respond to COM701, and these were selected based on our analysis of denim acid biomarker expression profiles and our clinical data. In this monotherapy expansion study, biopsies will be collected before and on COM7-1 treatment to allow retrospective analysis of our denim acid biomarker approach.
9:33 Additionally, we remain on track to begin our Phase 1-2 triple combination study, testing COM701 with BNS of Devo and their investigational TG inhibitor in the second half of this year. Moving to our TG program, we were pleased to announce first patient dose in our Phase 1 dose escalation trial of COM902 in patients with advanced malignancies. This would enable us to clinically evaluate dual blockade of PDRIG and TIGIT inhibitory pathways in the genome axis. We are encouraged by the biopharma industry's increasing interest in TIGIT.
10:21 The potential clinical validation of the TIGIT pathway, combined with our encouraging signals of antitumor activity of COM701 as a monotherapy and in combination with PD-1 inhibitor further substantiates our hypothesis of the relevance of the DENAM axis and the PDR-IG pathway in immunology. This also serves as evidence in our view of the potential power and validity of our computational discovery platform. Having access to the only clinical stage PDR-IG asset to our knowledge highly differentiates us on testing the clinical relevance of these Xs, and we look forward to driving our three parallel clinical studies in 2020, COM701 monotherapy, COM701-OVIVO, Antibiotic Inhibitor-Triple Combination Therapy, and COM902 dose escalation.
11:23 Furthermore, in early Q1, We provided certain anticipated milestones and data readouts. At this time, despite the COVID-19 pandemic, we do not expect delays in our earlier guidance. We still plan to initiate and complete enrollment in our COM701 monotherapy expansion cohort with initial data expected to be disclosed in the first half of 2021. disclose initial data from our COM902 dose escalation study in 2021, and initiate our triple combination study with BMS in the second half of 2020.
12:12 Having said that, we're monitoring the situation on an ongoing manner, and we will share with you any material changes in our outlook, if these may arise. While some of our sites are directing resources to COVID-19, overall to date we have not observed significant impact on patient enrollment and monitoring. This could be for a number of reasons. First, the patient population we are enrolling is comprised of patients with advanced disease who have exhausted all available standards of care therapies. We are still in stages in which we are recruiting a very small number of patients.
12:58 In addition to these two aspects, we believe that the number of clinical sites participating in our studies, our careful selection of a mix of academic and dedicated Phase I clinical trial sites that see only patients with advanced cancer, and the diligence of the clinical investigators all contribute to our current position. But again, this may change, and we are in daily communication with the site and are actively monitoring the situation. We have also continued our steady progress in strengthening our intellectual property portfolio, aiming to keep the position of our assets as strong as possible.
13:47 Adding to our previously granted composition of matter and use patent in the US and Europe, we are announcing Q1, a European patent for the use of any anti-PGRID antibody that activates T-cells and or NK-cells in the treatment of cancer, an additional European composition of matter patent for COM701 and backup antibodies for use in the treatment of cancer, and the U.S. Patent for methods of screening of anti-PDRG antibodies that inhibit the binding of PDRG and PDRL2. We were proud to recently announce the publication of preclinical data originating from our collaboration with Bayer on Bay 190-5254, a first-in-class immuno-oncology therapeutic antibody targeting IDR2.
14:48 which we discovered computationally and which is currently being evaluated by Bayer in a Phase 1 study in advanced solid tumor. We believe this also serves as important validation of the power of our platform to computationally identify untapped drug targets while also establishing ILDR2 as a new immune checkpoint and a drug target being pursued in clinical studies. The recent accomplishments have contributed to COMPIGEN's dramatic evolution over the past several quarters. We transitioned to a clinical stage company with a growing body of encouraging data that support our unique approach as a target discovery and drug development biotech company employing cutting-edge Computational Biology to discover new biological pathways and novel drug targets to develop first-class drug candidates.
15:53 This quarter, and despite challenging market conditions, we were pleased to announce an approximately $79 million public offering that we believe is testament to the growing confidence in our company, and the power of our approach and capabilities. Our strengthened cash balance empowers us to continue our strong execution, pursue our strategic clinical plans and advance our early stage programs to propel our company forward. Before turning the call over to Henry, I would like to add that I'm very proud of our employees and Grateful for their dedication.
16:42 These recent accomplishments and our tremendous progress over the past several quarters were made possible due to their hard work, drive, faith and commitment for which I'm incredibly grateful, particularly given the extraordinary circumstances we're now facing. Under these circumstances, we remain focused on advancing our pipeline program and maintain positive momentum to achieve our long-term goals. I look forward to providing updates throughout the year. And with this, I will now turn the call over to Henry. Henry?
17:25 Thank you, Anat, and good afternoon and good morning to everyone. As Anat mentioned, we have continued to report encouraging data from the ongoing COM701 phase 1 dose escalation study, which now includes new data from the monotherapy arm, COM701 20 milligrams per kilogram IVQ4 waves, the combination arm with nivolumab or Opdivo, and an update on the two patients that were ongoing study treatments in arm A, COM701 monotherapy at our last data disclosure at SITC 2019. Last week at AACR, we presented clinical data from our ongoing phase one clinical study designed to assess the safety and tolerability of escalating doses of COM701 monotherapy, as well as in combination with nivolumab in patients with advanced solid tumors who have exhausted all available standard therapies.
18:20 This data builds upon our prior dataset presented at SITC in 2019, which included 13 patients in an A in the first seven-dose cohorts of the monotherapy dose escalation arm of the study. The data we reported demonstrated that COM701 was well tolerated with no dose-limiting toxicities across all seven dose cohorts, with dosing up to 10 mg per kg IV every three weeks. In addition, the data provided initial encouraging signals of anti-tumor activity with 9 of 13 patients, or 69%, having a best time point anti-tumor activity of stable disease. These results are particularly noteworthy given the highly refractory and all-coma patient population who had received a median of 7 and a maximum of 15 prior lines of therapy prior to enrollment on this study.
19:16 We also reported anti-tumor activity in patients with microsatellite stereocolorectal cancer, a challenging tumor type that is typically unresponsive to checkpoint inhibitors and for which there are no approved therapies. We reported stable disease in five of six patients with MSS CRC, or 83%. Three of the six patients with colorectal cancer had KRAS mutation. All three patients had stable disease under study. The data informed our decision to include eligible patients with microsatellite stable colorectal cancer as an indication in our upcoming expansion cohort. In our oral virtual presentation at AACR, were reported the completion of all eight dose-level cohorts in monotherapy, which now includes data from 16 patients and the first three or four dose-level cohorts in the combination arm with 12 patients.
20:14 Importantly, COM701 was well-tolerated with no dose-limiting toxicities through 20 mg per kg IDQ for weeks as monotherapy and 10 mg per kg IDQ for weeks in combination with nivolumab. None of the patients discontinued study treatment due to the toxicity of any of the studied drugs. The most frequent adverse events observed in either arm was fatigue reported in 39% of patients and all between grade one and grade two. Majority of the adverse events in the safety analysis set reported in the study on both arms were grade one to two adverse events in 10 out of 18 patients or 56% in arm A and 7 out of 13 patients or 54% in MB, demonstrating no increased toxicity with a combination of COM701 and nivolumab.
21:09 We also reported preliminary PK data that is supportive of dosing of COM701 IVQ for weeks at the doses evaluated. Having previously reported at SITC 2019 that the PK profile of COM701 homotherapy permits IVQ for weeks dosing, This new data permits us flexibility with the schedule abusing of COM701. We continue to report encouraging anti-tumor activity of COM701 immunotherapy and now in combination with Nivolumab. We reported two patients with confirmed partial responses, a patient with microsatellite-stable platinum-resistant primary peritoneal cancer, ongoing study treatment for 25 weeks on AMA, and another patient with micro-satellite-stable colorectal cancer with KRAS mutation and the ongoing study treatment for 44 weeks.
22:05 Notably, these ongoing responses in micro-satellite-stable colorectal cancer and primary peritoneal cancer, a type of ovarian cancer, are supportive of our biomarker-informed selection of indications for the monotherapy expansion cohorts. We also reported a high disease control rate in both monotherapy and combination therapy arms. 69% or 11 out of 16 patients in the monotherapy arm and 75% or nine out of 12 patients for the combination arm. This means that 69% of patients enrolled in arm A and 75% of patients enrolled in arm B derived some clinical benefits on the study.
22:51 We are encouraged by the durability of study treatment considering the patient population enrolled on the study, patients who have exhausted all available standard therapies. Across AMA and AMB, we observed durable responses of at least stable disease for over six months in six of 28, that is 21% of patients. Of the 12 patients enrolled in AMB, six remain on study with a number of patients on treatment for over 200 days and some approaching the one-year mark. Taken together, these data are encouraging and support our preclinical hypothesis that inhibition of PVRIG leads to enhanced activation of anti-tumor immune response leading to tumor growth inhibition.
23:44 The next step in our COM701 clinical program is the Moodle therapy cohort expansion. This study arm will utilize a biomarker-informed strategy to focus on tumor types based on our preclinical PVRL2 expression data and dose escalation clinical results that we believe are most likely to respond to treatment with COM-701. The COM-701 monotherapy cohort expansion will enroll approximately 20 patients with advanced nostril cell, lung, ovarian, breast, endometrial, and microsatellite stable colorectal cancer all of whom have exhausted all available standard therapies. We also will be examining adenam axis biomatter approach in biopsies obtained from patients before and during treatment to conduct retrospective biomatter analysis to inform on treatment outcomes.
24:44 Operational aspects for this part of the study are underway. An important clinical milestone of the quarter was the initiation of our Phase 1 study of COM902, our proprietary TIGIT inhibitor. This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of COM902 in patients with advanced malignancies who have exhausted currently available standard of care therapies. We believe having a wholly owned antithesis antibody is important for our overall clinical development plan and a significant differentiator in this space.
25:32 Enrollment of patients into the COM902 dose escalation study is ongoing. We look forward to initiating our phase 1-2 triple combination study of COM701 with nivolumab and BMS986207. Bristol-Myers Squibb's Investigational CIGIT Inhibitor. We believe this is an important step towards testing our overall hypothesis on the role of the genome axis and other pathways that intersect with it, such as PVRL2 slash PVRIG, PVR slash CIGIT, and PDL1 slash PD1. Our objective is to hopefully demonstrate that disabling the genome axis and other pathways that intersect with it will translate to clinically meaningful treatment outcomes for patients, such as overall response rates, progression-free survival, duration of response, and possibly overall survival.
26:35 This planned phase one slash two open-label study will evaluate the safety, tolerability, and anti-stomach activity of COM701 in combination with Obedevo and DMS-986207 in selected tumor types, namely ovarian cancer, endometrial cancer, and in biomarker-driven arm of tumor types with high expression of PVRL2. The study will dose escalate COM701 with fixed doses of nivolumab and DMS-986207. We remain on track to begin the study in the second half of this year. It is clear that these are exciting times that come to this. and we thank the patients participating in our clinical studies and their families.
27:22 We also thank the investigators and study site personnel whose dedication, despite the unprecedented challenges of COVID-19, make our studies possible. To date, the impact on our studies has been limited. And as mentioned, we are in daily communication with the clinical study sites and are monitoring the situation very closely. We remain committed to the advancement of all our clinical programs and are increasingly hopeful that we will help address the significant unmet needs of so many cancer patients by expanding the population that may benefit from immunotherapies from cold to care. With that, I will turn the call over to Ari.
28:08 Thank you, Henry. Good morning and good afternoon to everyone. The first quarter of 2020 was transformational for CompuGen. Today, we are better positioned financially as reflected by our improved cash balance and linear expense structure and are enjoying greater market recognition. We are now well positioned to advance our pipeline, both clinical and early stage, and achieve our corporate goals. Our financial results for the first quarter of 2020 released this morning continue to reflect the expenses associated with our ongoing Phase 1 study for COM701 and initiation of the Phase 1 study for COM902, as well as our strong financial position derived from a recent public offering, with gross proceeds of approximately $79 million, including approximately $4.3 million received from the exercise of the underwriters option which occurred after the end of the first quarter.
29:19 R&D expenses for the first quarter of 2020 were $4.7 million compared with $6.3 million for the same period of 2019. This decrease of over 25% is mostly attributed to the restructuring process we announced at the end of the first quarter of 2019 Thank you very much. the dose escalation of COM701 in combination with Opdivo and the dose escalation study for COM902.
30:16 Net loss for the first quarter of 2020 was $7.1 million or 10 cents per basic and diluted chair compared with a net loss of $8.4 million or 14 cents per basic and diluted chair for the same period of 2019. As of March 31, 2020, we had approximately $121 million in cash and cash-related accounts, compared with approximately $44 million as of December 31, 2019. The company had no debt in either period. The increase in our cash balances of approximately $77 million during the first quarter is mostly attributed to the approximately $70 million of net proceeds received in a recent public offering approximately $5.2 million received from exercise of foreigns and approximately $7.2 million received from exercise of employee options, offset by operating expenses and working capital.
31:23 As noted earlier, an additional amount of approximately $4 million of net proceeds related to the recent and the public offering was received after the end of the first quarter and is not reflected in the cash balances as of March 31st, 2020. Total cash expenditures on a full year basis is still expected to be approximately $27 million. As Henry and Anat have indicated, at the moment, we are not experiencing any significant impact from COVID-19 on our operations and as such, Our cash expenditure outlook for the year has not changed at this time.
32:08 It is important to note that the thoughtful approach in which we manage our cash resource in the past will continue. At the moment, based on our current plans, we do not expect to increase our level of expenditures in a significant way going forward. Now, before opening the call for questions, I would like to thank our investors for the continued support and confidence in Compugen. Thank you for joining us today. And on behalf of the entire Compugen family, we hope you stay safe and healthy. Thank you. And with that, we will now open the call for questions. Thank you, ladies and gentlemen. At this time, we'll begin the question and answer session. If you have a question, please press star one.
32:54 If you wish to decline from the polling process, please press star two. If you are using speaker equipment, kindly lift the headset before pressing the numbers. Please stand by while we poll for your questions. The first question is from Mark Breidenbach of Oppenheimer. Please go ahead. Hey, guys. This is Matt for Mark. Thanks for taking our questions and congrats on the recent progress. Anat, I apologize if I missed this, but I just wanted to clarify whether the triplet trial will be all comers by design You are going to be deploying a biomarker-guided eligibility strategy.
33:28 Yeah, hi, Matt. So, obviously, dose escalation is an all-comer study, but we designed for three arms. One is for ovarian, the other one for endometrial, and the third one is biomarker-driven PVRL2 height. Patient Population. Different type of indication. Okay, got it. That's very helpful. And then maybe if you could just provide more detail on the development strategy for 902. Should we expect that Phase I trial to really look a lot like the COM701 trial did? And in the future, are you planning on using biomarker-guided expansion cohorts?
34:21 So right now, obviously, this is a study, it's a dose escalation as a monotherapy, and it is being designed to be tested in patients with advanced malignancies who've exhausted all available standard therapies. Going forward, I'll remind that we developed COM902 in order to make sure that as a complementary asset to COM701, We want to make sure that we can execute on our Comp7-1 strategy and prove the hypothesis that we identified scientifically, first computationally and then by experimental procedures preclinically, that TGIT and PVRIG pathways are working in parallel and in complement.
35:12 and for that we would like to advance COM-902 to be able to test it in combination with COM-701. Obviously we are conducting a triplet study with Obdivo and the TGT inhibitor BMS which is great and it's advancing our timelines and it's win-win for Compogen and BMS but we want to make sure that we keep pushing our strategy forward and test COM902 plus COM701 also independent of PD-1 and that's important for us. Having said that, we have a critical stage asset. There is interest in the industry with respect to TGIT and we're waiting to see the data and the efficacy for TGIT. and we will make plans as we move forward for COM902 also independently of COM701.
36:14 So the first priority is making sure that it's complementary to COM701. But then we will make sure that we pursue the value of this asset as much as possible. With respect to biomarker strategy, Obviously, TIGIT is part of the DENAM axis, and we as a company, we were looking at all these axes, at all the different pathways, and our approach looking at the different family members, sorry, at the different axis members by means of chemistry, we will probably also extend it to the TIGIT studies. But it's not at this stage. And we will share our biomarker strategy for our own COM902 program when we'll have it ready.
37:08 Got it. That makes sense. And then just maybe one more, if I may. So just in terms of data readouts, are you still planning on providing data from the doublet combination dose escalation cohorts sometime in the second half?
37:26 We actually advanced timelines and presented data at AACR. Most of the combination study, dose escalation study is already shared with the public. Obviously, we'll have more data, but we'll find the time to present it. The next data readout, as I stated in the prepared remarks, are starting in the first half of 2021. And we'll find the time to combine this data as well in our next disclosure. Great. Thanks for taking our questions. The next question is from Asika Gordonat, Fund Trust, Robinson Humphrey. Please go ahead.
38:19 Hey there. This is Al-Anon for Asika. Thanks for taking my question. I guess following up on the point that you had made on the biopharma interest in TIGIT and also taking a look at the potential efficacy of TIGIT with the Roche data coming up at ASCO, I guess we were curious on what you'd be looking for for, I guess, a meaningful readout of that data. And I guess, would you be able to give us an idea of how that translates to Either your triplet combination that's planned to start in the second half or for just your COM902 program.
38:59 Thanks. So obviously we're not familiar with any of the data and we will look to see. It's only, you know, I think that the interest of the industry is mainly by the actions or the announcement that Roche made. But we will wait to see. We don't put any threshold to what is an activity for the TIGIT. I think that this is still, you know, it still remains to be seen what is the activity of TIGIT. From our perspective, we believe that the three pathways together blocking them in a situation where in patient populations where the three pathways are operative, and we believe based on our data, the research and the preclinical data that this should enhance anti-tumor activity and the relative contribution of TGT on this front, it remains to be seen and we don't put any threshold on this.
40:14 We will test it on our own. More than that, combining TGT and PVRIG may generate a different outcome in a different patient population and different indications. So we're not putting any threshold to the initiation of our studies. We will start our studies and we will show the relative value of each and how they're operating together as a monotherapy for COM701 Com71 in combination with Com902, so blocking PVRIG and TGIT, which, by the way, should also enhance DNAM, and blocking the triple pathway, which may block three negative regulatory pathways and stimulate a cost-tumulatory pathway, which is DNAM.
41:07 So it's really looking at the full perspective, so currently no specific threshold. We will be very happy to see for two reasons. First, it will continue to support our hypothesis, but also remember, we discovered it computationally and published it at the time that Genentech published it in 2009, so we're very proud. If this will be a clinically validated pathway, this will be great for us, but But we're not putting any limits to start our own studies. All right. That's very helpful. And then one more, if I may, on COM902.
41:57 I guess with the first patient dose already, how should we think about maybe the different dose cohorts that you'd be considering going forward?
42:09 I'll let Henry relate to it, but I think that, you know, we take it one step at a time, data-driven, and we'll just, you know, but Henry, would you like to address it?
42:21 Yes, thank you so much, Anat. Yes, we'll take it one step at a time, but we're going to follow what we've typically done in dose escalation for most of these therapies. So it could be a rules-based design. Rules-based meaning there's a certain number of patients that are evaluated. We'll see over a predefined number of days, that's the first cycle, typically, to see if there are any DLTs. The number of patients that we're going to enroll will depend on how long each of these DLT evaluation period for the number of subjects that will be enrolled will be. So for example, if you enroll one subject, it's much faster than if you enroll three subjects. So the rule space that I'm talking about is something similar to maybe a three plus three design or a single subject cohort, but essentially the rules are based on the predefined items or parameters for DLT evaluation. So it's going to be similar to what we have on COM701 in Griffith.
43:30 All right. Got it. Thank you. And congratulations on progress. Thank you, Speaker. The next question is from Colin White of Jefferies. Please go ahead.
43:42 Hello. It's Colin White from Jefferies here. A couple of questions, if I may, on TIDGET. The first question I had was just about whether there is anything in any of the preclinical data or anything you have seen for your tidget, which in any way makes you think it may be differentiated from any of the competitors' tidgets. And then the second question I have, just to follow on from the previous questions, was you've mentioned there that if you saw with Roche's data, It's an interesting question. So just with respect to differentiation,
44:45 Our antibody is an ultra-high affinity antibody, so that's a differentiating factor, but we don't know how it will translate in the clinic, so I wouldn't think about our TG test completely differentiating. I think that the key differentiation for us at Compugen is the fact that we have Comp701, we have a clinical stage PVRG antibody, and we think that that it is needed in specific patient populations, in specific cancer indications. So this is our key differentiator. Talking about the data being overwhelming and our own TGIT, as I said, I don't consider at this stage our TGIT as a key differentiator for the company. But I do think that, and that's similar to what I was saying to Estika, for us, the bar for digit activity will just serve us as a starting point to show whether we can enhance with PVRIG and with PVRIG plus PD1 blocker.
46:05 So it's really, from our perspective, it's a start. So no, I think that we still need to prove the denim axis hypothesis, the involvement of the three pathways, and the fact that what we view as enhancement of antitumor activity is really occurring. And I'll just say that our first data with the monotherapy and also with the combination in the dose escalation, it's encouraging because it supports what we're saying for quite some time. It's initial, but it's highly supportive.
46:47 That's great, Sanjay. Thank you, Carly. The next question is from Tony Butler of Roth Capital. Please go ahead. Good morning. This is Tasha San in place for Tony. Thank you for taking my question. Number one, is there any data on PPRIG and or TIGIT mRNA in normal lymphocytes versus those found in the tumor?
47:21 Are you specifically interested in the mRNA, or why is it specifically mRNA? I can answer about the protein level, which I think is more important. There is an overexpression in the tumor microenvironment of the PVRGS compared to normal cells. I mean, you know, in the tumor microenvironment, things change. If there's a differentiating data, whether it's your internal data or whether you would like to point me towards an existing publication, either or is good enough.
48:05 Sure. So, as I said, in the tumor microenvironment, the PGRID levels are overexpressed as compared to normal cells, and I just refer to the fact that it's a protein level and not the mRNA level. I'm not sure that I know to answer the data for the mRNA level, but I think it's of less interest. Sure. And have you observed Any changes in these biomarkers in tumor cells in response to external stress? For example, let's say either radiation or application of chemo.
48:56 So, PDR-IG is expressed on the T-cells. within the tumor microenvironment. And by the way, on the most exhausted CD8 plus cells, which is expressed together with TG10PD1. I'm not sure that I have the answer with respect to external stimuli offhand at this moment. No worries. Thank you for your time.
49:31 Thank you. This concludes our question and answer session. I will now turn the call back to CompuGIS President and CEO. Dr. Cohen-Dayag, would you like to make your concluding statement?
49:42 Yes, thank you. Our 2020 is off to a strong start. Our ongoing COM701 phase 1 study is progressing well We recently disclosed encouraging data from both the monotherapy and the combination dose escalation arms and we are gearing up to initiate the next phase of the trial, the monotherapy expansion cohorts during this quarter. We're also on track to begin in the second half of 2020 the triple combination study for COM701 with BMS of DIVO and investigational anti-tigit inhibitor which will allow a hypothesis on the denim axis. With a stronger balance sheet, we're well positioned to continue executing on this expanded clinical development plan, invest in our early stage programs to drive our future therapeutic pipeline and maintain this positive momentum.
50:43 Thank you all for joining us today. We look forward to updating you on our progress through the year. Stay safe and healthy. Thank you.
Follow Compugen Ltd. into a list and get an email when it puts out news.
President and CEO
Chief Medical Officer
CFO and COO
Analyst, Jefferies